Core Viewpoint - Yinuo Kang Medical Technology (Suzhou) Co., Ltd. is progressing with its initial public offering (IPO) guidance, with Huatai United Securities as the advisory institution, focusing on fundraising project preparations and feasibility assessments [2][4] Group 1: Company Overview - Yinuo Kang was established in 2014 and specializes in the research, production, sales, and service of high-end ultrasound and ophthalmic surgical instruments [4] - The company is headquartered in the Suzhou area of the China (Jiangsu) Pilot Free Trade Zone and has a production base and some R&D collaboration projects in Hefei, as well as a research center in California, USA [4] - Yinuo Kang has developed core technologies in high-end medical devices, including ultrasound energy platforms, electrosurgical energy platforms, ophthalmic instruments, and minimally invasive surgical robots, with a focus on surgical instrument systems and high-value consumables [4] Group 2: Intellectual Property and Shareholding - The company has applied for 245 domestic patents and 52 international patents to protect its innovations [4] - The controlling shareholder is Liu Shougong, who directly holds 38.98% of the shares, while Liu Shougong and Luo Wei together control 65.87% of the company [4] - Liu Shougong serves as the chairman, and Luo Wei is the manager and director of the company [4] Group 3: IPO Guidance Progress - The IPO guidance work began in August 2025 and is currently being reported for the period from August to September 2025 [2] - The guidance team, led by Sun Shenghu, includes members Wang Zhaoqian, Lian Ke, Tang Chengwei, and Pang Zhiyuan [2] - The team is focusing on the company's operational status and future development strategies, urging the company to prepare for fundraising projects and assess their feasibility and necessity [2]